Ligand, Janssen Enter R&D Deal
12 July 2018 - 7:48AM
Dow Jones News
Micah Maidenberg
Subsidiaries of Ligand Pharmaceutical Inc. (LGND) and Johnson
& Johnson (JNJ) have entered into a research-and-development
agreement focused on a "transgenic chicken platform" aimed at
generating and discovering antibodies for humans, according to a
securities filing.
Ligand's company Crystal Bioscience Inc., and Janssen Research
& Development LLC, which is part of the Janssen Pharmaceutical
Cos. of Johnson & Johnson, agreed to work together on Ligand's
development of the platform, the filing said.
Under the deal, Ligand will be able to earn milestone payments
contingent on various deliverables and will be able to sell the
platform to others in the market.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
July 11, 2018 17:33 ET (21:33 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024
